{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:33:47Z","timestamp":1793406827037,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12020-017-1341-2","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T05:29:42Z","timestamp":1496813382000},"page":"272-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus"],"prefix":"10.1007","volume":"57","author":[{"given":"J.","family":"Hohendorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Szopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Skupien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kapusta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zapala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Platek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mrozinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Parpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Glodzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ludwig-Galezowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kiec-Wilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Klupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Malecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"issue":"12","key":"1341_CR1","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00125-010-1799-4","volume":"53","author":"BM Shields","year":"2010","unstructured":"B.M. Shields, S. Hicks, M.H. Shepherd, K. Colclough, A.T. Hattersley, S. Ellard, Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53(12), 2504\u20132508 (2010)","journal-title":"Diabetologia"},{"issue":"3","key":"1341_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/ann.34.3.207.217","volume":"34","author":"A Stride","year":"2002","unstructured":"A. Stride, A.T. Hattersley, Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann. Med. 34(3), 207\u2013216 (2002)","journal-title":"Ann. Med."},{"issue":"5","key":"1341_CR3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00125-011-2090-z","volume":"54","author":"J Kropff","year":"2011","unstructured":"J. Kropff, M.P. Selwood, M.I. McCarthy, A.J. Farmer, K.R. Owen, Prevalence of monogenic diabetes in young adults: a community-based, cross-sectional study in oxfordshire, UK. Diabetologia 54(5), 1261\u20131263 (2011)","journal-title":"Diabetologia"},{"key":"1341_CR4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/B978-0-12-800174-5.00016-8","volume":"95","author":"K Yamagata","year":"2014","unstructured":"K. Yamagata, Roles of HNF1\u03b1 and HNF4\u03b1 in pancreatic \u03b2-cells: lessons from a monogenic form of diabetes (MODY). Vitam. Horm. 95, 407\u2013423 (2014)","journal-title":"Vitam. Horm."},{"issue":"9","key":"1341_CR5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1055\/s-0035-1559605","volume":"123","author":"M Szopa","year":"2015","unstructured":"M. Szopa, J. Wolkow, B. Matejko, J. Skupien, T. Klupa, I. Wybranska, I. Trznadel-Morawska, B. Kiec-Wilk, M. Borowiec, M.T. Malecki, Prevalence of retinopathy in adult patients with GCK-MODY and HNF1A-MODY. Exp. Clin. Endocrinol. Diabetes 123(9), 524\u2013528 (2015)","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"4","key":"1341_CR6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001250050931","volume":"41","author":"B Isomaa","year":"1998","unstructured":"B. Isomaa, M. Henricsson, M. Lehto, C. Forsblom, S. Karanko, L. Sarelin, M. H\u00e4ggblom, L. Groop, Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 41(4), 467\u2013473 (1998)","journal-title":"Diabetologia"},{"issue":"9392","key":"1341_CR7","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(03)14571-0","volume":"362","author":"ER Pearson","year":"2003","unstructured":"E.R. Pearson, B.J. Starkey, R.J. Powell, F.M. Gribble, P.M. Clark, A.T. Hattersley, Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362(9392), 1275\u20131281 (2003)","journal-title":"Lancet"},{"issue":"4","key":"1341_CR8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1464-5491.2009.02690.x","volume":"26","author":"M Shepherd","year":"2009","unstructured":"M. Shepherd, B. Shields, S. Ellard, O. Rubio-Cabezas, A.T. Hattersley, A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet. Med. 26(4), 437\u2013441 (2009)","journal-title":"Diabet. Med."},{"issue":"Pt 5","key":"1341_CR9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004563213483458","volume":"50","author":"TJ McDonald","year":"2013","unstructured":"T.J. McDonald, S. Ellard, Maturity onset diabetes of the young: identification and diagnosis. Ann. Clin. Biochem. 50(5), 403\u2013415 (2013)","journal-title":"Ann. Clin. Biochem."},{"issue":"4","key":"1341_CR10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/embo-reports\/kvd071","volume":"1","author":"M Pontoglio","year":"2000","unstructured":"M. Pontoglio, D. Pri\u00e9, C. Cheret, A. Doyen, C. Leroy, P. Froguel, G. Velho, M. Yaniv, G. Friedlander, HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO. Rep. 1(4), 359\u2013365 (2000)","journal-title":"EMBO. Rep."},{"issue":"7","key":"1341_CR11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2337\/dc14-2769","volume":"38","author":"AJ Chakera","year":"2015","unstructured":"A.J. Chakera, A.M. Steele, A.L. Gloyn, M.H. Shepherd, B. Shields, S. Ellard, A.T. Hattersley, Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care 38(7), 1383\u20131392 (2015)","journal-title":"Diabetes Care"},{"issue":"3","key":"1341_CR12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jama.2013.283980","volume":"311","author":"AM Steele","year":"2014","unstructured":"A.M. Steele, B.M. Shields, K.J. Wensley, K. Colclough, S. Ellard, A.T. Hattersley, Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 311(3), 279\u2013286 (2014)","journal-title":"JAMA"},{"issue":"3","key":"1341_CR13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1530\/EJE-14-0713","volume":"172","author":"M Szopa","year":"2015","unstructured":"M. Szopa, G. Osmenda, G. Wilk, B. Matejko, J. Skupien, B. Zapala, W. Mlynarski, T. Guzik, M.T. Malecki, Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients. Eur. J. Endocrinol. 172(3), 277\u2013283 (2015)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"1341_CR14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00125-013-3075-x","volume":"57","author":"A Stride","year":"2014","unstructured":"A. Stride, B. Shields, O. Gill-Carey, A.J. Chakera, K. Colclough, S. Ellard, A.T. Hattersley, Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia 57(1), 54\u201356 (2014)","journal-title":"Diabetologia"},{"issue":"5","key":"1341_CR15","first-page":"377","volume":"26","author":"E Guenat","year":"2000","unstructured":"E. Guenat, G. Seematter, J. Philippe, E. Temler, E. Jequier, L. Tappy, Counterregulatory responses to hypoglycemia in patients with glucokinase gene mutations. Diabetes Metab. 26(5), 377\u2013384 (2000)","journal-title":"Diabetes Metab."},{"issue":"11","key":"1341_CR16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.20452\/pamw.3164","volume":"125","author":"M Szopa","year":"2015","unstructured":"M. Szopa, A. Ludwig-Galezowska, P. Radkowski, J. Skupien, B. Zapala, T. Platek, T. Klupa, B. Kiec-Wilk, M. Borowiec, W. Mlynarski, P. Wolkow, M.T. Malecki, Genetic testing for monogenic diabetes using targeted next-generation sequencing in patients with maturity-onset diabetes of the young. Pol. Arch. Med. Wewn. 125(11), 845\u2013851 (2015)","journal-title":"Pol. Arch. Med. Wewn."},{"issue":"9","key":"1341_CR17","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1007\/s00125-013-2962-5","volume":"56","author":"S Ellard","year":"2013","unstructured":"S. Ellard, H. Lango Allen, E. De Franco, S.E. Flanagan, G. Hysenaj, K. Colclough, J.A. Houghton, M. Shepherd, A.T. Hattersley, M.N. Weedon, R. Caswell, Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia 56(9), 1958\u20131963 (2013)","journal-title":"Diabetologia"},{"issue":"3","key":"1341_CR18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11892-012-0275-6","volume":"12","author":"MA Abdul-Ghani","year":"2012","unstructured":"M.A. Abdul-Ghani, L. Norton, R.A. DeFronzo, Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr. Diab. Rep. 12(3), 230\u2013238 (2012)","journal-title":"Curr. Diab. Rep."},{"issue":"5","key":"1341_CR19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","volume":"85","author":"B Komoroski","year":"2009","unstructured":"B. Komoroski, N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, L. Li, M. Pfister, Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol. Ther. 85(5), 520\u2013526 (2009)","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"1341_CR20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"B. Komoroski, N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, M. Pfister, Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85(5), 513\u2013519 (2009)","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"1341_CR21","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.2337\/diacare.27.8.1859","volume":"27","author":"JB McGill","year":"2004","unstructured":"J.B. McGill, T.G. Cole, W. Nowatzke, S. Houghton, E.B. Ammirati, T. Gautille, M.J. Sarno, Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27(8), 1859\u20131865 (2004)","journal-title":"Diabetes Care"},{"issue":"6","key":"1341_CR22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2337\/dc06-1910","volume":"29","author":"KM Dungan","year":"2006","unstructured":"K.M. Dungan, J.B. Buse, J. Largay, M.M. Kelly, E.A. Button, S. Kato, S. Wittlin, 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29(6), 1214\u20131219 (2006)","journal-title":"Diabetes Care"},{"issue":"6","key":"1341_CR23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1464-5491.1999.00093.x","volume":"16","author":"ES Kilpatrick","year":"1999","unstructured":"E.S. Kilpatrick, B.G. Keevilt, K.L. Richmond, P. Newland, G.M. Addison, Plasma 1,5-anhydroglucitol concentrations are influenced by variations in the renal threshold for glucose. Diabet. Med. 16(6), 496\u2013499 (1999)","journal-title":"Diabet. Med."},{"issue":"8","key":"1341_CR24","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc07-2334","volume":"31","author":"J Skupien","year":"2008","unstructured":"J. Skupien, S. Gorczynska-Kosiorz, T. Klupa, K. Wanic, E.A. Button, J. Sieradzki, M.T. Malecki, Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. Diabetes Care 31(8), 1496\u20131501 (2008)","journal-title":"Diabetes Care"},{"key":"1341_CR25","doi-asserted-by":"publisher","unstructured":"M. Szopa, M. Kapusta, B. Matejko, T. Klupa, T. Koblik, B. Kiec-Wilk, M. Borowiec, M.T. Malecki, Comparison of glomerular filtration rate estimation from serum creatinine and cystatin C in HNF1A-MODY and other types of diabetes. J. Diabetes Res. (2015). doi: 10.1155\/2015\/183094","DOI":"10.1155\/2015\/183094"},{"issue":"3","key":"1341_CR26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"E.R. DeLong, D.M. DeLong, D.L. Clarke-Pearson, Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3), 837\u2013845 (1988)","journal-title":"Biometrics"},{"issue":"Suppl. A","key":"1341_CR27","first-page":"A16","volume":"5","author":"2016 Guidelines on the management of diabetic patients","year":"2016","unstructured":"2016 Guidelines on the management of diabetic patients, A position of diabetes Poland. Clin. Diabet. 5(Suppl. A), A16\u2013A18 (2016)","journal-title":"Clin. Diabet."},{"key":"1341_CR28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthew, Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetologia 58, 429\u2013442 (2015).","journal-title":"Diabetologia"},{"issue":"22","key":"1341_CR29","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG OUTCOME investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373(22), 2117\u20132128 (2015)","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"1341_CR30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12020-016-0943-4","volume":"53","author":"RP Monica Reddy","year":"2016","unstructured":"R.P. Monica Reddy, S.E. Inzucchi, SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53(2), 364\u2013372 (2016)","journal-title":"Endocrine"},{"issue":"10","key":"1341_CR31","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","volume":"36","author":"RA DeFronzo","year":"2013","unstructured":"R.A. DeFronzo, M. Hompesch, S. Kasichayanula, X. Liu, Y. Hong, M. Pfister, L.A. Morrow, B.R. Leslie, D.W. Boulton, A. Ching, F.P. LaCreta, S.C. Griffen, Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes. Care 36(10), 3169\u20133176 (2013)","journal-title":"Diabetes. Care"},{"issue":"3","key":"1341_CR32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13300-016-0192-9","volume":"7","author":"AK Ovsyannikova","year":"2016","unstructured":"A.K. Ovsyannikova, O.D. Rymar, E.V. Shakhtshneider, V.V. Klimontov, E.A. Koroleva, N.E. Myakina, M.I. Voevoda, ABCC8-related maturity-onset diabetes of the young (MODY12): clinical features and treatment perspective. Diabetes Ther. 7(3), 591\u2013600 (2016)","journal-title":"Diabetes Ther."},{"issue":"9","key":"1341_CR33","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2337\/db12-0052","volume":"61","author":"JJ Liu","year":"2012","unstructured":"J.J. Liu, T. Lee, R.A. DeFronzo, Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61(9), 2199\u20132204 (2012)","journal-title":"Diabetes"},{"issue":"10","key":"1341_CR34","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","volume":"62","author":"MA Abdul-Ghani","year":"2013","unstructured":"M.A. Abdul-Ghani, R.A. DeFronzo, L. Norton, Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans. Diabetes 62(10), 3324\u20133328 (2013)","journal-title":"Diabetes"},{"issue":"2","key":"1341_CR35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"V. Vallon, S.C. Thomson, Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2), 215\u2013225 (2017)","journal-title":"Diabetologia"},{"issue":"3","key":"1341_CR36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/152091503765691839","volume":"5","author":"JB Buse","year":"2003","unstructured":"J.B. Buse, J.L. Freeman, S.V. Edelman, L. Jovanovic, J.B. McGill, Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes. Technol. Ther. 5(3), 355\u2013363 (2003)","journal-title":"Diabetes. Technol. Ther."},{"issue":"2","key":"1341_CR37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc09-1246","volume":"33","author":"A Pal","year":"2010","unstructured":"A. Pal, A.J. Farmer, C. Dudley, M.P. Selwood, B.A. Barrow, R. Klyne, J.P. Grew, M.I. McCarthy, A.L. Gloyn, K.R. Owen, Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 33(2), 252\u2013257 (2010)","journal-title":"Diabetes Care"},{"issue":"2","key":"1341_CR38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/dme.12066","volume":"30","author":"SA Mughal","year":"2013","unstructured":"S.A. Mughal, R. Park, N. Nowak, A.L. Gloyn, F. Karpe, H. Matile, M.T. Malecki, M.I. McCarthy, M. Stoffel, K.R. Owen, Apolipoprotein M can discriminate HNF1A\u2013MODY from type 1 diabetes. Diabet. Med. 30(2), 246\u2013250 (2013)","journal-title":"Diabet. Med."},{"issue":"11","key":"1341_CR39","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00125-011-2261-y","volume":"54","author":"G Thanabalasingham","year":"2011","unstructured":"G. Thanabalasingham, N. Shah, M. Vaxillaire, T. Hansen, T. Tuomi et al.. A large multi-centreeuropean study validates high-sensitivity C-reactive protein (hsCRP) as a clinical biomarker for the diagnosis of diabetes subtypes. Diabetologia 54(11), 2801\u20132810 (2011)","journal-title":"Diabetologia"},{"issue":"3","key":"1341_CR40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s12020-015-0627-5","volume":"50","author":"N Nowak","year":"2015","unstructured":"N. Nowak, J. Hohendorff, I. Solecka, M. Szopa, J. Skupien, B. Kiec-Wilk, W. Mlynarski, M.T. Malecki, Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus. Endocrine 50(3), 643\u2013649 (2015)","journal-title":"Endocrine"},{"key":"1341_CR41","doi-asserted-by":"publisher","unstructured":"H. Qiu, A. Novikov, V. Vallon, Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab. Res. Rev. (2017). doi: 10.1002\/dmrr.2886 [Epub ahead of print]","DOI":"10.1002\/dmrr.2886"},{"issue":"9","key":"1341_CR42","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.2337\/dc13-0058","volume":"36","author":"S Pruhova","year":"2013","unstructured":"S. Pruhova, P. Dusatkova, D. Neumann, E. Hollay, O. Cinek, J. Lebl, Z. Sumnik, Two cases of diabetic ketoacidosis in HNF1A-MODY linked to severe dehydration: is it time to change the diagnostic criteria for MODY? Diabetes Care 36(9), 2573\u20132574 (2013)","journal-title":"Diabetes Care"},{"key":"1341_CR43","doi-asserted-by":"publisher","unstructured":"Egan A.M., Cunningham A., Jafar-Mohammadi B., Dunne F.P., Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young. BMJ Case Reports. (2015). doi: 10.1136\/bcr-2014-209163","DOI":"10.1136\/bcr-2014-209163"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-017-1341-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-017-1341-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:43:17Z","timestamp":1750293797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-017-1341-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["1341"],"URL":"https:\/\/doi.org\/10.1007\/s12020-017-1341-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,7]]}}}